

EudraCT number: 2015-003892-31

A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combination in ER-positive metastatic breast cancer patients. (BIOPER STUDY)

Primary Clinical Efficacy End-Point

Clinical Benefit Rate (ITT Population)

Clinical Benefit Rate according RECIST	
N	32
No	21 (65.6%)
Yes	11 (34.4%)
Two-Sided 95% CI	(18.6% ; 53.2%)
One-sided p-value (H0:CBR<=5%)	<0.0001